Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 19/20 | 0.67 |
| ▸ | ITGB2 | P05107 | 18/20 | 0.67 |
| ▸ | ICAM1 | P05362 | 18/20 | 0.67 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22296844 | 0.94 | ITGAL (0.59) | ITGALITGB2ICAM1PRMT5WDR77 | |
| SCHEMBL23176585 | 0.94 | ITGAL (0.59) | ITGALITGB2ICAM1PRMT5WDR77 | |
| SCHEMBL17991461 | 0.92 | ITGAL (0.76) | ITGALITGB2ICAM1 | |
| SCHEMBL16731604 | 0.84 | ITGAL (0.68) | ITGALITGB2ICAM1 | |
| SCHEMBL17991454 | 0.82 | ITGAL (0.65) | ITGALITGB2ICAM1 | |
| SCHEMBL22296843 | 0.82 | ITGAL (0.64) | ITGALITGB2ICAM1 | |
| SCHEMBL19158522 | 0.80 | ITGAL (0.77) | ITGALITGB2ICAM1 | |
| SCHEMBL16307479 | 0.78 | ITGB2 (0.69) | ITGALITGB2ICAM1 | |
| SCHEMBL4755996 | 0.77 | ITGB2 (0.80) | ITGALITGB2ICAM1 | |
| SCHEMBL12169926 | 0.77 | ITGAL (0.65) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | SARCODE CORPORATION (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155176-A1 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB2 11/4885ICAM1 3/4885 |
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | VCAM1, ITGB1, ICAM1 | ITGAL 5/4885ITGB2 11/4885ICAM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.